Introduction

A patent infringement dispute over infant feeding technology reached a negotiated resolution when Dr. Brown’s Company and Graco Children’s Products, Incorporated agreed to settle in principle, ending Case No. 3:22-cv-00704 before the Wisconsin Western District Court. Filed in December 2022 and closed in July 2024, the case centered on U.S. Patent No. US10028890B2, covering a dual configuration bottle assembly — a product category commanding significant commercial attention in the competitive baby products market.

The settlement, which concluded after 585 days of litigation, reflects a growing trend across consumer product patent disputes: parties increasingly prefer negotiated outcomes over the cost, uncertainty, and exposure of full trial proceedings. For patent attorneys tracking infant product IP litigation, in-house counsel managing licensing exposure, and R&D teams developing competing bottle technologies, this case offers meaningful insights into assertion strategy, venue selection, and the practical dynamics of settlement timing in design-adjacent patent disputes.

Case Overview

The Parties

The Patent at Issue

The asserted patent, U.S. Patent No. US10028890B2 (Application No. US14/151513), covers a dual configuration bottle assembly — a technology enabling infant feeding bottles to function across multiple configurations, likely addressing ergonomic, venting, or feeding-mode adaptability. Patent claims in this space typically involve structural elements of the bottle body, nipple assembly, venting components, and configuration-switching mechanisms. Design patents are registered with the U.S. Patent and Trademark Office (USPTO) and protect ornamental appearance rather than functional technology.

The Accused Product

The complaint targeted Graco’s dual configuration bottle assembly products. The commercial significance is substantial: baby bottle design patents and utility patents directly affect retail shelf positioning, licensing leverage, and the ability to exclude competitors from fast-moving consumer product categories.

Legal Representation

Plaintiff (Dr. Brown’s Company): Armstrong Teasdale LLP and Reinhart, Boerner & Van Deuren SC, represented by Charlie M. Jonas, Jessica Hutson-Polakowski, Marc W. Vander Tuig, and Monica Ann Mark.

Defendant (Graco Children’s Products): Godfrey & Kahn SC and Meunier, Carlin & Curfman LLC, represented by Gregory Joseph Carlin, Jennifer Lynn Gregor, Kendall W. Harrison, and Robert Leonard.

Both sides engaged experienced regional and national IP litigation counsel, signaling that each party treated this dispute as commercially material.

Litigation Timeline & Procedural History

Dr. Brown’s Company filed suit in the Wisconsin Western District Court, a venue with established patent litigation infrastructure and proximity relevant to at least one party’s operational footprint. The choice of a Midwestern federal district, rather than historically plaintiff-favored venues like the Eastern District of Texas or the District of Delaware, may reflect jurisdictional connections or strategic considerations around local rules and judicial docket efficiency.

The case proceeded at the first instance (district court) level, meaning no appellate proceedings were initiated before settlement. The 585-day duration — approximately 19 months — is broadly consistent with district court patent cases that resolve before trial, encompassing pleadings, early motion practice, likely claim construction proceedings, and pre-trial discovery before the parties reached their settlement in principle.

No specific summary judgment rulings, claim construction orders, or trial dates were disclosed in the available case record. The absence of appellate escalation suggests neither party pursued an early dispositive ruling that fundamentally altered litigation posture.

The Verdict & Legal Analysis

Outcome

The case resolved via negotiated settlement, with plaintiff’s counsel filing notice that both parties had “reached a settlement in principle” and were finalizing agreement terms. The parties jointly requested suspension of all upcoming deadlines and anticipated filing a stipulation and order for dismissal. The case was formally closed on July 19, 2024.

Specific financial terms, royalty rates, licensing arrangements, and any injunctive relief provisions were not disclosed in publicly available case records — a common feature of privately negotiated IP settlements, particularly in consumer product markets where confidentiality serves both parties’ competitive interests.

Verdict Cause Analysis

The sole stated cause of action was patent infringement under U.S. patent law. Because the case settled before trial and no published claim construction order or summary judgment ruling is available in the provided record, the precise legal theories adjudicated — such as literal infringement versus doctrine of equivalents, or any validity challenges Graco may have raised — cannot be confirmed from available data.

What the settlement timeline does suggest is instructive: resolution after nearly 19 months indicates the parties likely completed substantial discovery and potentially claim construction proceedings before negotiating. Settlements occurring post-claim construction, but pre-trial, are strategically significant — claim construction rulings typically clarify the scope of asserted claims and recalibrate each side’s litigation risk assessment, frequently catalyzing resolution.

Legal Significance

While the settlement produces no binding precedent on claim construction or infringement standards for dual configuration bottle assemblies, the case contributes to the observable pattern that consumer product patent disputes in this category — infant feeding technology — are resolved through private agreement at high rates. This reflects the parties’ mutual interest in avoiding public disclosure of design details, sales data, and licensing terms that full trial proceedings would expose.

For practitioners tracking US10028890B2 specifically, the settlement leaves the patent’s validity and claim scope formally unchallenged in this proceeding, preserving Dr. Brown’s Company’s ability to assert it in future enforcement actions.

Strategic Takeaways

For Patent Holders: Dr. Brown’s decision to file in Wisconsin rather than a traditionally plaintiff-favorable venue demonstrates that strong patents in well-defined product categories can support assertion strategies across multiple jurisdictions. Maintaining a robust continuation strategy around core bottle assembly technology extends portfolio life and licensing leverage.

For Accused Infringers: Graco’s engagement of dual regional and national counsel (four attorneys across two firms) reflects best practice for large consumer goods defendants — resource the defense appropriately from filing to avoid adverse early rulings. Early investment in claim construction strategy can materially influence settlement dynamics.

For R&D Teams: Freedom-to-operate (FTO) analysis on dual configuration bottle assemblies must account for US10028890B2 remaining an active, asserted patent. Design-around strategies should evaluate the structural claims of the patent before product development advances to production stage.

Industry & Competitive Implications

The infant feeding products market is characterized by intense IP activity. Specialty brands like Dr. Brown’s Company have built competitive moats around patented venting and configuration technologies, using litigation and licensing as tools to preserve market position against larger-volume manufacturers and private label competition.

For Graco, a settlement outcome — while avoiding the risk of an adverse judgment — still represents legal expenditure and potential licensing obligations that affect product cost structures. Companies of Graco’s scale regularly face assertion from specialty IP holders and must balance settlement economics against the precedent-setting risk of adverse rulings.

This case also reflects a broader licensing trend: parties in consumer product patent disputes frequently prefer confidential settlement terms over public trial outcomes, preserving flexibility for future commercial relationships, including potential co-licensing or distribution arrangements that open litigation would foreclose.

R&D teams at juvenile product companies should treat this case as a signal that dual configuration bottle assembly technology is actively patrolled IP territory. Competitive product development in this space requires current FTO clearance, not reliance on dated analyses.